Table 2 Cumulative 1-year incidences of acute liver injury (and ancillary outcome) and hazard ratios for each type of NOAC compared to VKA, in patients with no prior liver disease (main study population).
Type of OAC | N patients | N events | Follow-up in days (mean ± SD) | Crude cumulative 1-year incidence with 95% CI (per 10,000) | Cumulative 1-year incidence with 95% CI after IPTW* (per 10,000) | Crude HR with 95% CI | HR after IPTW with 95% CI |
|---|---|---|---|---|---|---|---|
Hospitalised acute liver injury | |||||||
VKA | 220,367 | 117 | 339 ± 70 | 5.6 (4.7–6.7) | Dabigatran: 5.3 (4.6–6.0) Rivaroxaban: 5.1 (4.4–5.8) Apixaban: 5.3 (4.6–6.1) | Reference | Reference |
Dabigatran | 51,737 | 26 | 350 ± 49 | 5.1 (3.5–7.5) | 6.2 (4.0–8.3) | 0.92 (0.60–1.41) | 1.17 (0.79–1.75) |
Rivaroxaban | 99,408 | 46 | 351 ± 48 | 4.7 (3.6–6.3) | 7.2 (4.5–9.8) | 0.85 (0.60–1.19) | 1.41 (1.05–1.91) |
Apixaban | 62,503 | 29 | 349 ± 51 | 4.8 (3.3–6.9) | 4.4 (2.4–6.3) | 0.85 (0.57–1.28) | 0.82 (0.53–1.25) |
Elevation of transaminases (proxy, ancillary outcome) | |||||||
VKA | 220,367 | 7537 | 333 ± 80 | 358.0 (350.2–366.1) | Dabigatran: 348.1 (342.5–353.6) Rivaroxaban: 343.2 (336.9–349.5) Apixaban: 349.3 (342.9–355.7) | Reference | Reference |
Dabigatran | 51,737 | 1353 | 345 ± 61 | 267.3 (253.6–281.7) | 297.2 (280.5–314.0) | 0.74 (0.70–0.79) | 0.85 (0.81–0.90) |
Rivaroxaban | 99,408 | 2877 | 345 ± 61 | 295.6 (285.1–306.4) | 334.1 (320.9–347.2) | 0.82 (0.79–0.86) | 0.97 (0.93–1.01) |
Apixaban | 62,503 | 1958 | 343 ± 64 | 320.7 (307.0–335.0) | 351.7 (334.8–368.7) | 0.89 (0.85–0.94) | 1.01 (0.96–1.06) |
